Lack of Effect of Methylphenidate on Serum Growth Hormone (GH), GH-Binding Protein, and Insulin-like Growth Factor I

Authors:
  • ASAviva Silbergeld
    Aviva Silbergeld
  • SESofia Eldar
    Sofia Eldar
  • NLNathaniel Laor
    Nathaniel Laor
  • LWLeo Wolmer
    Leo Wolmer
  • SKSharon Koren
    Sharon Koren
  • RWRaphael Weitz
    Raphael Weitz
  • DIDov Inbar
    Dov Inbar
  • ARAhuva Reiss
    Ahuva Reiss
  • RERina Eshet
    Rina Eshet
  • RWRonit Weizman
    Ronit Weizman

Abstract
The aim of this study was to assess the growth hormone (GH) axis in methylphenidate (MPH)-treated and untreated boys with attention-deficit and hyperactivity disorder (ADHD), by evaluating serum GH, GH-binding protein (GHBP) activity, and insulin-like growth factor I (IGF-I) levels as compared to age-matched normal controls. Blood samples were taken from 42 boys (aged 6–16 years) diagnosed as having ADHD according to DSM-III-R criteria and confirmed by using the Schedule for Affective Disorder and Schizophrenia for school-age children (K[Kiddle]-SADS). A total of 21 patients were treated with MPH (5–20 mg/day; 0.15–0.77 mg/kg/day), on a drug holiday protocol, for 1–36 months, and 21 were drug naive. A total of 46 age-matched normal boys at height and weight within normal range served as controls. No significant differences were detected between the MPH-treated ADHD children, the untreated ADHD children, and the control children on fasting serum GH levels, GHBP activity, or IGF-I levels. Active treatment with MPH, in ADHD children on a drug holiday protocol, does not cause changes in GH axis as manifested by normal values of GH, GHBP, and IGF-I.